Mechanism of the Antihypertensive and Vasorelaxant Effects of the Flavonoid Tiliroside in Resistance Arteries

Abstract

Hypertension is a leading cause of death and disability globally, and its prevalence continues to accelerate. The cardiovascular effects of the flavonoid tiliroside have never been reported. In this work, using complementary in vivo and in vitro approaches, we describe the antihypertensive effect of tiliroside and the underlying mechanisms involved in the reduction of blood pressure. Tiliroside (1, 5 or 10 mg/kg) induced a dose-dependent long-lasting decrease in blood pressure in conscious DOCA-salt hypertensive rats that was accompanied by an increased heart rate. Tiliroside also induced a concentration-dependent vasodilation of mesenteric resistance arteries precontracted with phenylephrine. Removal of the endothelium or pretreatment of the preparation with L-NAME or indomethacin did not modify the vasodilator response for tiliroside. When vessels were precontracted with a high K⁺ (50 mM) solution, tiliroside exhibited a vasodilator effect similar to that observed in vessels precontracted with phenylephrine. Experiments carried out in nominally Ca²⁺-free solution showed that tiliroside antagonized CaCl₂-induced contractions. Moreover, tiliroside reduced the rise in intracellular Ca²⁺ concentration induced by membrane depolarization in vascular smooth muscle cells. Finally, tiliroside decreased the voltage-activated peak amplitude of the L-type Ca²⁺ channel current in freshly dissociated vascular smooth muscle cells from mesenteric arteries. Altogether, our results point to an antihypertensive effect of tiliroside due to a reduction in peripheral resistance through blockage of voltage-activated peak amplitude of the L-type Ca²⁺ channel in smooth muscle cells.

Key words

flavonoids - tiliroside - antihypertensive effect - vasodilation - mesenteric artery - Ca_V 1.2

• References

• 1 Palatini P, Casiglia E, Gąsowski J, Głuszek J, Jankowski P, Narkiewicz K, Saladini F, Stolarz-Skrzypek K, Tikhonoff V, Van Bortel L, Wojciechowska W, Kawecka-Jaszcz K. Arterial stiffness, central hemodynamics, and cardiovascular risk in hypertension. Vasc Health Risk Manag 2011; 7: 725-739
• 2 White RM, Rivera CO, Davison CB. Differential contribution of endothelial function to vascular reactivity in conduit and resistance arteries from deoxycorticosterone-salt hypertensive rats. Hypertension 1996; 27: 1245-1253
• 3 Cribbs LL. T-type Ca²⁺ channels in vascular smooth muscle: multiple functions. Cell Calcium 2006; 40: 221-230
• 4 Richard S. Vascular effects of calcium channel antagonists: new evidence. Drugs 2005; 65: 1-10
• 5 Wei D, He WY, Lv QZ. Effect of nisoldipine and olmesartan on endothelium-dependent vasodilation in essential hypertensive patients. CNS Neurosci Ther 2012; 18: 400-405
• 6 Yao LH, Jiang YM, Tomás-Barberán FA, Datta N, Singanusong R, Chen SS. Flavonoids in food and their health benefits. Plant Food Hum Nutr 2004; 59: 113-122
• 7 Riemersma RA, Rice-Evans CA, Tyrrel RM, Clifford MN. Tea flavonoids and cardiovascular health. QJM 2001; 94: 277-282
• 8 Kay CD, Hooper L, Kroon PA, Rimm EB, Cassidy A. Relative impact of flavonoid composition, dose and structure on vascular function: a systematic review of randomised controlled trials of flavonoid-rich food products. Mol Nutr Food Res 2012; 56: 605-616
• 9 Godse S, Mohan M, Kasture V, Kasture S. Effect of myricetin on blood pressure and metabolic alterations in fructose hypertensive rats. Pharm Biol 2010; 48: 494-498
• 10 Schinella GR, Tournier HA, Máñez S, de Buschiazzo PM, Del Carmen Recio M, Ríos JL. Tiliroside and gnaphaliin inhibit human low density lipoprotein oxidation. Fitoterapia 2007; 78: 1-6
• 11 Sala A, Recio MC, Schinella GR, Máñez S, Giner RM, Cerdá-Nicolás M, Ríos JL. Assessment of the anti-inflammatory activity and free radical scavenger activity of tiliroside. Eur J Pharmacol 2003; 461: 53-61
• 12 Qiao W, Zhao C, Qin N, Zhai HY, Duan HQ. Identification of trans-tiliroside as active principle with anti-hyperglycemic, anti-hyperlipidemic and antioxidant effects from Potentilla chinesis . J Ethnopharmacol 2011; 135: 515-521
• 13 Goto T, Teraminamia A, Lee JY, Ohyamaa K, Funakoshia K, Kim YI, Hirai S, Uemura T, Yu R, Takahashi N, Kawada T. Tiliroside, a glycosidic flavonoid, ameliorates obesity-induced metabolic disorders via activation of adiponectin signaling followed by enhancement of fatty acid oxidation in liver and skeletal muscle in obese-diabetic mice. J Nutr Biochem 2012; 23: 768-776
• 14 Rezende BA, Cortes SF, De Sousa FB, Lula IS, Schmitt M, Sinisterra RD, Lemos VS. Complexation with beta-cyclodextrin confers oral activity on the flavonoid dioclein. Int J Pharm 2009; 367: 133-139
• 15 Gross V, Luft FC. Exercising restraint in measuring blood pressure in conscious mice. Hypertension 2003; 41: 879-881
• 16 Rezende BA, Lemos VS, Cortes SF. Activation of nitric oxide modulator effect by isometric contraction in rat resistance arteries. J Cardiovasc Pharmacol 2006; 47: 51-54
• 17 Pinho JF, Medeiros MA, Capettini LS, Rezende BA, Campos PP, Andrade SP, Cortes SF, Cruz JS, Lemos VS. Phosphatidylinositol 3-kinase-δ up-regulates L-type Ca²⁺ currents and increases vascular contractility in a mouse model of type 1 diabetes. Br J Pharmacol 2010; 161: 1458-1471
• 18 Silva DA, Costa DA, Silva D, Souza MFV, Agra MF, Medeiros IA, Barbosa-Filho JM, Braz-Filho R. Glycosyl flavonoids from Herissantia tiubae (K. Schum) Brizicky (Malvaceae) and preliminary tests of kaempferol 3, 7-di-O-a-L-rhamnopyranoside. Rev Bras Farmacogn 2005; 15: 23-25
• 19 Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo Jr. JL, Jones DW, Materson BJ, Oparil S, Wright Jr. JT, Roccella EJ. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute, National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206-1252
• 20 Cortes SF, Rezende BA, Corriu C, Medeiros IA, Teixeira MM, Lopes MJ, Lemos VS. Pharmacological evidence for the activation of potassium channels as the mechanism involved in the hypotensive and vasorelaxant effect of dioclein in rat small resistance arteries. Br J Pharmacol 2001; 133: 849-858
• 21 Rezende BA, Cortes SF, Lemos VS. Mechanisms involved in the vasodilator effect of the flavanol floranol in rat small mesenteric arteries. Planta Med 2004; 70: 465-467
• 22 Saponara S, Carosati E, Mugnai P, Sgaragli G, Fusi F. The flavonoid scaffold as a template for the design of modulators of the vascular Ca_v 1.2 channels. Br J Pharmacol 2011; 164: 1684-1697
• 23 Nelson MT, Quayle JM. Physiological roles and properties of potassium channels in arterial smooth muscle. Am J Physiol 1995; 268: C799-C822
• 24 Magnon M, Calderone V, Floch A, Cavero I. Influence of depolarization on vasorelaxant potency and efficacy of Ca²⁺ entry blockers, K⁺ channel openers, nitrate derivatives, salbutamol and papaverine in rat aortic rings. Naunyn Schmiedebergs Arch Pharmacol 1998; 358: 452-463
• 25 Bolton TB. Mechanisms of action of transmitters and other substances on smooth muscle. Physiol Rev 1979; 59: 606-718
• 26 Nelson MT, Standen NB, Brayden JE, Worley JF. Noradrenaline contracts arteries by activating voltage-dependent calcium channels. Nature 1988; 336: 382-385
• 27 Jim K, Harris A, Rosenberger LB, Triggle DJ. Stereoselective and non-stereoselective effects of D 600 (methoxyverapamil) in smooth muscle preparations. Eur J Pharmacol 1988; 76: 67-72
• 28 Kochegarov AA. Pharmacological modulators of voltage-gated calcium channels and their therapeutical application. Cell Calcium 2003; 33: 145-162
• 29 Medeiros MA, Nunes XP, Barbosa-Filho JM, Lemos VS, Pinho JF, Roman-Campos D, Medeiros IA, Araujo DA, Cruz JS. (S)-reticuline induces vasorelaxation through the blockade of L-type Ca²⁺ channels. Naunyn Schmiedebergs Arch Pharmacol 2009; 379: 115-125